Crossmark

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

Crossref DOI link: https://doi.org/10.1186/s13052-021-01187-1

Published Online: 2022-01-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lanari, Marcello

Venturini, Elisabetta

Pierantoni, Luca

Stera, Giacomo

Castelli Gattinara, Guido

Esposito, Susanna Maria Roberta

Favilli, Silvia

Franzoni, Emilio

Fusco, Eleonora

Lionetti, Paolo

Maffeis, Claudio

Marseglia, Gianluigi

Massella, Laura

Midulla, Fabio

Zanobini, Alberto

Zecca, Marco

Villani, Alberto

Staiano, Annamaria

Galli, Luisa https://orcid.org/0000-0002-7912-3366
,

Blasi, Francesco

Di Giorgio, Angelo

Donà, Daniele

Licari, Amelia

Martinelli, Massimo

Mastrangelo, Antonio

Miraglia del Giudice, Michele

Nicolini, Giangiacomo

Pugliese, Fabrizio

Striano, Pasquale

Valerio, Giuliana
License Information

Text and Data Mining valid from 2022-01-12

Version of Record valid from 2022-01-12
More Information

Article History

Received: 18 October 2021

Accepted: 22 November 2021

First Online: 12 January 2022

Declarations

:

: Not applicable.

: All authors have agreed to the publication.

: All authors declared that there is no competing interest.

Document is current

Any future updates will be listed below